Genscript Biotech Corporation (GNNSF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNNSF representa a Genscript Biotech Corporation, una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 58/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Genscript Biotech Corporation (GNNSF) Resumen de Asistencia Médica y Tuberías
Genscript Biotech Corporation is a global biotechnology company focused on life science research products and services, biologics development, industrial synthetic biology, and cell therapy. With a presence in North America, Europe, Asia Pacific, and China, Genscript serves diverse sectors, including pharmaceuticals, diagnostics, and agriculture.
Tesis de Inversión
Genscript Biotech Corporation presents a notable research candidate within the biotechnology sector, driven by its diverse service offerings and global reach. Key value drivers include the continued expansion of its biologics development services and the growth of its cell therapy segment, particularly in the development of CAR-T therapies. The company's established presence in key markets like North America, Europe, and China provides a solid foundation for future growth. However, potential risks include regulatory hurdles, competition from established players, and the inherent uncertainties associated with drug development. Investors should monitor the progress of Genscript's clinical trials and its ability to maintain a competitive edge in the rapidly evolving biotechnology landscape.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Genscript Biotech Corporation operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
- The company was founded in 2002 and is headquartered in Nanjing, China.
- Genscript Biotech Corporation has a market capitalization of $3.41 billion as of 2026-03-17.
- The company employs 5568 individuals.
- Genscript Biotech Corporation serves customers in North America, Europe, the People's Republic of China, Japan, and other Asia Pacific regions.
Competidores y Pares
Fortalezas
- Diverse service offerings across multiple segments of the biotechnology industry.
- Global presence and established customer base.
- Proprietary technologies and intellectual property.
- Strong reputation and brand recognition.
Debilidades
- Reliance on outsourced research and development spending.
- Exposure to regulatory risks and uncertainties.
- Competition from established players in the biotechnology industry.
- Dependence on key personnel and scientific expertise.
Catalizadores
- Upcoming: Progress in clinical trials for cell therapy candidates.
- Ongoing: Expansion of biologics development services.
- Ongoing: Penetration of industrial synthetic biology products.
- Ongoing: Geographic expansion into new markets.
- Ongoing: Strategic partnerships and acquisitions.
Riesgos
- Potential: Regulatory hurdles and delays in drug approvals.
- Potential: Competition from established players in the biotechnology industry.
- Potential: Economic downturn and reduced research and development spending.
- Ongoing: Technological obsolescence and disruption.
- Ongoing: Dependence on key personnel and scientific expertise.
Oportunidades de crecimiento
- Expansion of Biologics Development Services: Genscript can capitalize on the increasing demand for biologics development services by expanding its capabilities in antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development. The global biologics market is projected to reach $457 billion by 2026, presenting a significant growth opportunity for Genscript. Timeline: Ongoing.
- Growth in Cell Therapy Segment: The cell therapy market, particularly CAR-T therapies, is experiencing rapid growth due to its potential in treating liquid and solid tumors. Genscript's focus on discovering and developing CAR-T therapies positions it to benefit from this trend. The global CAR-T therapy market is expected to reach $4.9 billion by 2027. Timeline: Ongoing.
- Penetration of Industrial Synthetic Biology Products: Genscript can expand its presence in the industrial synthetic biology market by developing and producing industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The global industrial enzymes market is projected to reach $7.0 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
- Geographic Expansion: Genscript can further expand its global presence by penetrating new geographic markets, particularly in emerging economies with growing healthcare sectors. This expansion can be achieved through strategic partnerships, acquisitions, or organic growth. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Genscript can pursue strategic partnerships and acquisitions to expand its service offerings, access new technologies, and strengthen its market position. These partnerships can provide access to complementary expertise and resources, accelerating growth and innovation. Timeline: Ongoing.
Oportunidades
- Expansion of biologics development services.
- Growth in cell therapy segment.
- Penetration of industrial synthetic biology products.
- Strategic partnerships and acquisitions.
Amenazas
- Economic downturn and reduced research and development spending.
- Technological obsolescence and disruption.
- Increased competition and price pressure.
- Adverse regulatory changes and clinical trial failures.
Ventajas competitivas
- Proprietary technologies and intellectual property in gene synthesis and protein engineering.
- Established reputation and brand recognition in the life science research market.
- Global presence and extensive customer base.
- Integrated service offerings across multiple segments of the biotechnology industry.
Acerca de GNNSF
Founded in 2002 and headquartered in Nanjing, China, Genscript Biotech Corporation has evolved into a key player in the life science industry. The company operates through four distinct segments. The Life Science Services and Products segment offers a range of research services, including gene synthesis, molecular cloning, and antibody development, catering to basic biology studies, pharmaceutical discovery, and disease diagnostics. The Biologics Development Services segment provides antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development for pharmaceutical, biotech, government, and academic clients. The Industrial Synthetic Biology Products segment focuses on constructing non-pathogenic microbial strains and producing industrial enzymes for the food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment is dedicated to discovering and developing chimeric antigen receptor T-cell therapies for treating liquid and solid tumors. Genscript's global presence spans North America, Europe, China, Japan, and other Asia Pacific regions, serving a diverse customer base across various industries.
Qué hacen
- Provides gene synthesis and molecular cloning services.
- Offers oligonucleotide synthesis services.
- Specializes in protein engineering and peptide synthesis.
- Develops and produces antibody development services.
- Creates molecular diagnostics tools.
- Offers genome editing materials.
- Develops chimeric antigen receptor T-cell therapies.
Modelo de Negocio
- Provides fee-for-service research and development services to pharmaceutical and biotechnology companies.
- Sells life science research products, including reagents, kits, and instruments.
- Develops and commercializes cell therapies for the treatment of cancer.
- Generates revenue through licensing agreements and royalties.
Contexto de la Industria
Genscript Biotech Corporation operates within the rapidly growing biotechnology industry, driven by increasing demand for advanced research tools, biologics development services, and cell therapies. The market is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Genscript's diverse service offerings and global presence position it to capitalize on the increasing demand for outsourced research and development services from pharmaceutical and biotechnology companies. The company's focus on cell therapy also aligns with the growing interest in personalized medicine and innovative cancer treatments.
Clientes Clave
- Pharmaceutical companies
- Biotechnology companies
- Government research institutions
- Academic research institutions
- Food and chemical industries
Finanzas
Gráfico e información
Precio de la acción de Genscript Biotech Corporation (GNNSF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para GNNSF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GNNSF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para GNNSF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de GNNSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Weihui Shao
Unknown
Information on Weihui Shao's background is not available in the provided data. Details regarding his career history, education, and previous roles are currently unknown. Further research would be required to provide a comprehensive profile.
Historial: Information on Weihui Shao's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership are currently unknown. Further research would be required to provide a detailed assessment.
Información del mercado OTC de GNNSF
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading in these securities is often characterized by high risk and volatility compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low liquidity can make it difficult to exit positions.
- Higher price volatility compared to exchange-listed stocks.
- Potential for manipulation due to limited regulatory oversight.
- OTC Other stocks may be subject to delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Scrutinize the company's financials, if available, and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Be aware of the risks associated with investing in OTC Other securities.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 2002.
- Genscript Biotech Corporation has a significant number of employees (5568).
- The company has a market capitalization of $3.41 billion.
- Genscript Biotech Corporation has a global presence with operations in multiple regions.
- The company operates in the biotechnology industry, which is subject to regulatory oversight.
Preguntas Comunes Sobre GNNSF
¿Cuáles son los factores clave para evaluar GNNSF?
Genscript Biotech Corporation (GNNSF) actualmente tiene una puntuación IA de 58/100, indicando puntuación moderada. Fortaleza clave: Diverse service offerings across multiple segments of the biotechnology industry.. Riesgo principal a monitorear: Potential: Regulatory hurdles and delays in drug approvals.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de GNNSF?
GNNSF actualmente puntúa 58/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de GNNSF?
Los precios de GNNSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre GNNSF?
La cobertura de analistas para GNNSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en GNNSF?
Las categorías de riesgo para GNNSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory hurdles and delays in drug approvals.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de GNNSF?
La relación P/E para GNNSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está GNNSF sobrevalorada o infravalorada?
Determinar si Genscript Biotech Corporation (GNNSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de GNNSF?
Genscript Biotech Corporation (GNNSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- AI analysis is pending for GNNSF, limiting the availability of analyst insights.
- Information on Weihui Shao's background and track record is limited.